{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:07:49Z","timestamp":1756166869634,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007093"],"award-info":[{"award-number":["T32HL007093"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA180888","CA180819"],"award-info":[{"award-number":["CA180888","CA180819"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100129","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T12:07:58Z","timestamp":1749902878000},"page":"100129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-5293","authenticated-orcid":false,"given":"Suravi","family":"Raychaudhuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Elizabeth M.","family":"Percival","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-7773","authenticated-orcid":false,"given":"Jacob S.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bneo.2025.100129_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100129_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients\u2019 treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"42","author":"O\u2019Connell","year":"2024","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.bneo.2025.100129_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100129_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100129_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","article-title":"A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML","volume":"38","author":"Garcia-Manero","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100129_bib6","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100129_bib7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.bneo.2025.100129_bib8","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.bneo.2025.100129_bib9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr346","article-title":"Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients","volume":"23","author":"Brunnberg","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100129_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"Pautas","year":"2010","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.bneo.2025.100129_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2009-07-229492","article-title":"P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808","volume":"116","author":"Kolitz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100129_bib12","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms","volume":"32","author":"Halpern","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100129_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100129_bib14","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","article-title":"Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"104","author":"Halpern","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100129_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2022-157126","article-title":"Single versus double induction with \u201c7+3\u201d containing 60 versus 90 mg daunorubicin for newly diagnosed AML: results from the randomized controlled SAL Dauno-Double trial","volume":"140","author":"R\u00f6llig","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100129_bib16","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1080\/10428194.2021.1881512","article-title":"Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203","volume":"62","author":"Moseley","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.bneo.2025.100129_bib17","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:11:48Z","timestamp":1756127508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000640"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100129","relation":{},"ISSN":["2950-3280"],"issn-type":[{"type":"print","value":"2950-3280"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100129"}}